Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Pastorelli

Showing results (51-60 of 74) with videos related to

Pageof 8
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 29, 2015
IL-33 activates tumor stroma to promote intestinal polyposisRebecca L Maywald, Stephanie K Doerner, Luca Pastorelli, et al.
Gastroenterology|June 28, 2011
Spontaneous, immune-mediated gastric inflammation in SAMP1/YitFc mice, a model of Crohn's-like gastritisBrian K Reuter, Luca Pastorelli, Marco Brogi, et al.
Gastroenterology|October 3, 2020
Interleukin 33 Triggers Early Eosinophil-Dependent Events Leading to Metaplasia in a Chronic Model of Gastritis-Prone MiceCarlo De Salvo, Luca Pastorelli, Christine P Petersen, et al.
The American Journal of Pathology|February 25, 2016
IL-33 Drives Eosinophil Infiltration and Pathogenic Type 2 Helper T-Cell Immune Responses Leading to Chronic Experimental IleitisCarlo De Salvo, Xiao-Ming Wang, Luca Pastorelli, et al.
Clinical and Translational Science|September 15, 2021
Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort studyStefano Mazza, Nicole Piazza O Sed, Francesco Simone Conforti, et al.
Inflammatory Bowel Diseases|August 3, 2023
Prevalence of Disease-Related Malnutrition and Micronutrients Deficit in Patients with Inflammatory Bowel Disease: A Multicentric Cross-Sectional Study by the GSMII (Inflammatory Bowel Disease Study Group)Chiara Viganò, Andrea Palermo, Giacomo Mulinacci, et al.
Frontiers in Medicine|April 28, 2023
Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel diseaseMarco Vincenzo Lenti, Maria Lia Scribano, Livia Biancone, et al.
Alimentary Pharmacology & Therapeutics|October 25, 2021
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD studyCristina Bezzio, Alessandro Armuzzi, Federica Furfaro, et al.
Alimentary Pharmacology & Therapeutics|July 25, 2022
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Federica Crispino, et al.
Journal of Molecular Medicine (Berlin, Germany)|April 28, 2020
Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitisGiorgia Colombo, Nausicaa Clemente, Andrea Zito, et al.
Pageof 8

Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Proceedings of the National Academy of Sciences of the United States of America|April 29, 2015
IL-33 activates tumor stroma to promote intestinal polyposisRebecca L Maywald, Stephanie K Doerner, Luca Pastorelli, et al.
Gastroenterology|June 28, 2011
Spontaneous, immune-mediated gastric inflammation in SAMP1/YitFc mice, a model of Crohn's-like gastritisBrian K Reuter, Luca Pastorelli, Marco Brogi, et al.
Gastroenterology|October 3, 2020
Interleukin 33 Triggers Early Eosinophil-Dependent Events Leading to Metaplasia in a Chronic Model of Gastritis-Prone MiceCarlo De Salvo, Luca Pastorelli, Christine P Petersen, et al.
The American Journal of Pathology|February 25, 2016
IL-33 Drives Eosinophil Infiltration and Pathogenic Type 2 Helper T-Cell Immune Responses Leading to Chronic Experimental IleitisCarlo De Salvo, Xiao-Ming Wang, Luca Pastorelli, et al.
Clinical and Translational Science|September 15, 2021
Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort studyStefano Mazza, Nicole Piazza O Sed, Francesco Simone Conforti, et al.
Inflammatory Bowel Diseases|August 3, 2023
Prevalence of Disease-Related Malnutrition and Micronutrients Deficit in Patients with Inflammatory Bowel Disease: A Multicentric Cross-Sectional Study by the GSMII (Inflammatory Bowel Disease Study Group)Chiara Viganò, Andrea Palermo, Giacomo Mulinacci, et al.
Frontiers in Medicine|April 28, 2023
Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel diseaseMarco Vincenzo Lenti, Maria Lia Scribano, Livia Biancone, et al.
Alimentary Pharmacology & Therapeutics|October 25, 2021
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD studyCristina Bezzio, Alessandro Armuzzi, Federica Furfaro, et al.
Alimentary Pharmacology & Therapeutics|July 25, 2022
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Federica Crispino, et al.
Journal of Molecular Medicine (Berlin, Germany)|April 28, 2020
Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitisGiorgia Colombo, Nausicaa Clemente, Andrea Zito, et al.
Pageof 8